Taken together, our in vitro findings from a panel of NB cell lines suggest that the targeted inhibition of MEK1 by cobimetinib holds the potential to induce potent antitumor activity although there are subsets of cells that may be affected by this treatment. The gene discussed is MAP2K1; the disease is neuroblastoma.